Orgenesis Inc. has announced a regulatory issue concerning its listing status on the OTC Markets. On June 2, 2025, the OTC Markets Group informed the company that its common stock would be moved from the OTCQX tier to the Pink Limited tier, effective June 3, 2025. This decision follows Orgenesis Inc.'s failure to file its 10-K report for the period ending December 31, 2024, which is a requirement for continued qualification under the OTCQX Rules. The company did not address this deficiency within the 45-day cure period allowed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.